5.42

1.69% 0.09

After Hours: 5.38 -0.04 -0.74%

Sagimet Biosciences Inc (SGMT)

Overview News Price History Discussions Forecast

Sagimet Biosciences Inc stock is traded at $5.42, with a volume of 1.42M. It is up +1.69% in the last 24 hours and up +32.52% over the past month. Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Previous Close:

$5.33

Open:

$5.31

24h Volume:

1.42M

Relative Volume:

1.05

Market Cap:

$174.50M

Revenue:

Net Income/Loss:

$-27.92M

P/E Ratio:

-4.6996

EPS:

-1.1533

Net Cash Flow:

$-22.89M

1W Performance:

-9.52%

1M Performance:

+32.52%

6M Performance:

+25.46%

1Y Performance:

+32.84%

1-Day Range:

$5.18

$5.67

1-Week Range:

$4.92

$6.31

52-Week Range:

$2.13

$20.71

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1180)

Industry

Biotechnology (680)

Phone

(650) 561-8600

Address

155 BOVET RD., SUITE 303, SAN MATEO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SGMT's Discussions on Twitter

Sagimet Biosciences Inc Stock (SGMT) Latest News

08:33 AM

Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News

08:33 AM

Oct 31, 2024

HC Wainwright Reaffirms "Buy" Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat

Oct 31, 2024

Oct 30, 2024

Sagimet’s denifanstat enters Phase III trials for MASH treatment - Yahoo Finance

Oct 30, 2024

Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of - GlobeNewswire

Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash - Marketscreener.com

Oct 29, 2024

Oct 28, 2024

(SGMT) Technical Data - Stock Traders Daily

Oct 28, 2024

Oct 26, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Update - MarketBeat

Oct 26, 2024

Oct 18, 2024

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha

Oct 18, 2024

(SGMT) Investment Analysis and Advice - Stock Traders Daily

Oct 18, 2024

Oct 16, 2024

There is no way Sagimet Biosciences Inc (SGMT) can keep these numbers up - SETE News

Oct 16, 2024

Market Highlights: Sagimet Biosciences Inc (SGMT) Ends on a Low Note at 5.13 - The Dwinnex

Oct 16, 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLDThe Liver Meeting® 2024 - GlobeNewswire

Oct 16, 2024

Oct 15, 2024

How to interpret Sagimet Biosciences Inc (SGMT)’s stock chart patterns - US Post News

Oct 15, 2024

Sagimet Biosciences Inc’s Shares Reel: 42.19% Quarterly Revenue Decline Amid 167.12M Market Cap - The InvestChronicle

Oct 15, 2024

Oct 14, 2024

SGMT (Sagimet Biosciences Inc) may reap gains as insiders became active recently - Knox Daily

Oct 14, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in the Lancet Gastroenterology and Hepatology - Marketscreener.com

Oct 14, 2024

Oct 11, 2024

Sagimet Gains on Latest Numbers - Baystreet.ca

Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial - Investing.com

Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial By Investing.com - Investing.com UK

Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial - The Bakersfield Californian

Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from - GlobeNewswire

Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - StockTitan

Oct 11, 2024

Oct 10, 2024